The RPCI Data Bank and BioRepository (DBBR) collects and provides de-identified biospecimens and associated epidemiological and clinical data to meet the scientific needs of investigators.  Newly diagnosed patients are asked to contribute data and specimens to the DBBR prior to treatment.  Other patients with who have benign disease or advanced disease and have undergone treatment are also enrolled based on anticipated use of data and samples for research.  Additionally, non-patients (family members and friends of patients and community members) with no personal history of cancer are asked to participate in the biorepository as controls. 

Specimens and data are procured with protected health information (PHI) and de-identified prior to distribution to investigators with hypothesis driven IRB reviewed studies.  An extensive data collection and management system is in place to track informed consent, questionnaire collection and follow up, epidemiological questionnaire data, clinical data, biospecimens and their derivatives. 

RESEARCH SERVICES

• Availability of a bank of prospectively collected blood specimens (serum, plasma, buffy coat, red blood cells and DNA) from cancer patients, high risk individuals and healthy controls for research.  More Information About Banked Biospecimens
• Collection, linking and distribution of epidemiologic and clinical data with biospecimens.  More Information About Banked Data
• Study-specific biospecimen and data procurement to meet the needs of individual studies, including:
  • Participant identification, eligibility screening and informed consent
  • Serial biospecimen procurement prior to and throughout treatment
  • Study specific collection of biospecimens other than blood (buccal cells, sputum, and urine)
  • Procurement and distribution of fresh biospecimens
  • Collection of extended clinical and risk factor data
• More Information About Requesting Research Services
• The DBBR Team